Key Features • Provides treatment for glaucoma, other optic nerve diseases, and potentially any disease with neuronal dysfunction or loss. • Exploits an FDA approved drug, which may reduce clinical hurdles and time to market.
Technical Details:
According to the World Health Organization, glaucoma is the second leading cause of blindness in the world. One approach to treat glaucoma, and optic nerve diseases as well as other neurodegenerations, is to develop “neuroprotective” agents that promote the survival of neurons. JHU scientists have made a discovery that a known drug has a novel function as a neuroprotective agent that promotes the survival and neurite outgrowth of retinal ganglion cells (RGCs), the cells in the retina that die in glaucoma and whose loss leads to vision loss.
Looking for Partners:
Small molecule for treatment of glaucoma, optic nerve diseases, and other neurodegenerations.
